Andres Ruiz Briseno - 30 Jan 2026 Form 4 Insider Report for IDEAYA Biosciences, Inc. (IDYA)

Role: Title: SVP, Head of Finance and Investor Relations
Signature: /s/ Joshua Bleharski, as Attorney-in-Fact for Andres Ruiz Briseno
Issuer symbol: IDYA
Transactions as of: 30 Jan 2026
Net transactions value: +$37,044
Form type: 4
Filing time: 02 Feb 2026, 19:55:02 UTC
Previous filing: 28 Feb 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Ruiz Briseno Andres	Title: SVP, Head of Finance and Investor Relations	C/O IDEAYA BIOSCIENCES, INC., 5000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO	/s/ Joshua Bleharski, as Attorney-in-Fact for Andres Ruiz Briseno	02 Feb 2026	0001983118

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IDYA	Common Stock	Award	$15,861	+682	+2.8%	$23.26	25,213	29 Nov 2024	Direct	F1
transaction	IDYA	Common Stock	Award	$21,184	+1,253	+5%	$16.91	26,466	28 Nov 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IDYA	Stock Option (right to buy)	Award	$0	+80,000		$0.000000	80,000	30 Jan 2026	Common Stock	80,000	$32.19	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2	25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Remarks:

Title: SVP, Head of Finance and Investor Relations